发布求助
文献互助 智能选刊 最新文献

Skin therapy letter最新文献

筛选
英文 中文
Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib. 1型神经纤维瘤病的治疗进展：以塞鲁美替尼为重点。
Skin therapy letter Pub Date : 2025-09-01
Faith Cormier, Irene Lara-Corrales, Maxwell Sauder, Rebecca Levy
{"title":"Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib.","authors":"Faith Cormier, Irene Lara-Corrales, Maxwell Sauder, Rebecca Levy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neurofibromatosis type 1 (NF1) is a genetic condition inherited in an autosomal dominant pattern, but with 50% of cases caused by de novo mutations. Neurofibromin, the gene product in NF1, regulates the RAS/MAPK pathway, and mutation can lead to cell proliferation and the development of tumours. NF1 often presents in childhood with cafe-au-lait macules, skinfold freckling, nervous system tumours, and phenotypically variable findings. Plexiform neurofibromas (PN), a type of peripheral nerve sheath tumour seen in NF1, are typically histologically benign. However, PN can cause significant physical disfigurement, pain, and decreased quality of life, and have historically been difficult to treat. Selumetinib, a MEK inhibitor inhibiting the RAS/MAPK pathway, was Health Canada approved in 2022 for the treatment of symptomatic, inoperable PN in individuals with NF1 aged 2 years and older. Phase 1 and 2 trials have demonstrated reduced tumour size, decreased disfigurement and pain, and increased quality of life.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 5","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis. Upadacitinib治疗特应性皮炎的长期安全性和有效性综述。
Skin therapy letter Pub Date : 2025-09-01
Mohamad R Taha, Stephen K Tyring
{"title":"A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis.","authors":"Mohamad R Taha, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common inflammatory skin condition characterized by erythema and intense pruritus. A key pathway implicated in its pathogenesis is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. Upadacitinib, a JAK inhibitor, has been approved for the treatment of moderate-to-severe AD. This review evaluates the long-term safety and efficacy of upadacitinib in AD, incorporating findings from the Measure Up 1 and Measure Up 2 phase 3 studies.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 5","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis Lebrikizumab用于中重度特应性皮炎。
Skin therapy letter Pub Date : 2025-07-01
Leah Johnston, Susan Poelman, Andrei Metelitsa
{"title":"Lebrikizumab for Moderate-to-Severe Atopic Dermatitis","authors":"Leah Johnston, Susan Poelman, Andrei Metelitsa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that inhibits the activity of interleukin-13. In June 2024, lebrikizumab was approved by Health Canada for the treatment of moderate-to-severe AD in adults and adolescents who are 12 years of age and older, followed by US Food and Drug Administration approval in September 2024. This review provides an overview of data from clinical trials on the efficacy and safety of lebrikizumab in adult patients.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 4","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanodermatology Nanodermatology。
Skin therapy letter Pub Date : 2025-07-01
Claire Fason, Stephen K Tyring
{"title":"Nanodermatology","authors":"Claire Fason, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nanodermatology has been an emerging area of research and drug development in the last two decades. Nanodermatology lies at the intersection of nanotechnology, chemical engineering, biophysics, and pharmacology. Increasing research has yielded potential benefits of nanotechnology in the treatment of various skin conditions via enhanced transdermal drug delivery. Nanoparticles, defined as particles ranging from 1 to 1000 nanometers, have been more frequently explored for their potential role in targeted drug delivery systems. Nanocarriers, which include liposomes, ethosomes, and vesicle carriers, have been increasingly investigated to improve efficacy of various drugs via enhanced delivery to the target site. Many dermatologic conditions are preferentially treated with topical formulations to locally target the affected area and reduce systemic absorption, but these formulations are limited in their penetration. The ability of topical formulations to effectively deliver active ingredients to the target site is uncertain, therefore nanoparticles have been increasingly investigated as an approach to boost drug delivery to the deeper layers of the skin, improve absorption, and decrease adverse effects. Enhanced drug delivery utilizing nanoparticles has been successfully trialed for treatment of psoriasis, vitiligo, acne vulgaris, and atopic dermatitis in many research studies, however more investigation is needed prior to utilization in humans.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 4","pages":"8-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis 奈莫单抗用于治疗结节性痒疹和特应性皮炎。
Skin therapy letter Pub Date : 2025-05-01
Mohamad R Taha, Stephen K Tyring
{"title":"Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis","authors":"Mohamad R Taha, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion of interleukin-31 (IL-13) in the dermis and serum. Nemolizumab is a new IL-31 receptor antagonist that has shown high efficacy in the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in multiple phase 3 trials, with a good safety profile. A brief overview of PN and AD including highlights of the findings from three trials of nemolizumab in treating these disorders will be presented herein.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 3","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne. 一种治疗中重度痤疮的新型固定剂量三联疗法（IDP-126）。
Skin therapy letter Pub Date : 2025-05-01
Karen Michael, Jaefer Mohamad, Nuha Nasir, Jerry Tan
{"title":"A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne.","authors":"Karen Michael, Jaefer Mohamad, Nuha Nasir, Jerry Tan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126) is a novel fixed-dose triad gel combination approved by the US FDA October 2023 and by Health Canada August 2024 for the treatment of acne vulgaris in patients aged 12 years and older. IDP-126 was efficacious in moderate to severe acne compared to vehicle and component topical dyads in phase 2 and to vehicle in phase 3 randomized controlled studies. Efficacy outcomes were inflammatory and noninflammatory lesion counts and Evaluator's Global Severity Score. IDP-126 also had a favorable tolerability and safety profile.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 3","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roflumilast for the Treatment of Seborrheic Dermatitis: A Review. 罗氟司特治疗脂溢性皮炎的研究进展。
Skin therapy letter Pub Date : 2025-03-01
Austinn C Miller, Abigail E Watson, Marc J Inglese
{"title":"Roflumilast for the Treatment of Seborrheic Dermatitis: A Review.","authors":"Austinn C Miller, Abigail E Watson, Marc J Inglese","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD. Recent clinical trials have validated the efficacy of non-steroidal roflumilast 0.3% foam for the treatment of SD. In this review, we analyze the safety and efficacy profile of roflumilast 0.3% foam.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 2","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab's Efficacy and Utilization. 靶向IL-23治疗银屑病关节炎：古塞尔库单抗疗效及应用综述。
Skin therapy letter Pub Date : 2025-03-01
Alisha Kashyap, Kevin M Burningham, Stephen K Tyring
{"title":"Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab's Efficacy and Utilization.","authors":"Alisha Kashyap, Kevin M Burningham, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Psoriatic arthritis (PsA) is a chronic, inflammatory disease with heterogeneous clinical features. The pathogenesis of PsA involves a complex interplay of genetic, immunologic, and environmental factors, leading to the activation of the immune system and subsequent inflammation. Over the past decade, the understanding of the immune mechanisms underlying PsA has advanced significantly, particularly regarding the role of the interleukin-23/T helper 17 pathway in the disease process. Guselkumab, a novel IL-23 inhibitor, has emerged as a promising therapeutic option for PsA, offering an alternative to conventional therapies and other biologics. This review aims to summarize the current evidence on the efficacy, safety, and clinical utility of guselkumab in the treatment of PsA.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 2","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Hidradenitis Suppurativa: An Overview. 小儿化脓性汗腺炎：综述。
Skin therapy letter Pub Date : 2025-01-01
Jordanna Roesler, Allison Gregory, Wingfield Rehmus
{"title":"Pediatric Hidradenitis Suppurativa: An Overview.","authors":"Jordanna Roesler, Allison Gregory, Wingfield Rehmus","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory skin disease that significantly impacts the quality of life of patients.[1] HS is more common in adults and adolescents, although true incidence rates may be underestimated due to a lack of earlier recognition of HS in children.[2] Pediatric HS is a challenging clinical entity to diagnose and manage. Although considered uncommon, treatment of pediatric HS can drastically improve psychosocial well-being and should be considered in children presenting with recurring painful skin nodules, abscesses, scarring and sinus tracts. Multiple comorbidities are associated with pediatric HS, including depression, anxiety, inflammatory bowel disease, metabolic syndrome, and obesity.[3] Medical management of pediatric HS poses a unique challenge given the paucity of literature surrounding efficacy and long-term treatment outcomes in pediatric patients. The purpose of this article is to discuss the epidemiology, pathogenesis, comorbidities, and management of pediatric HS.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143011719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Update on the Clinical Management of Cutaneous Leishmaniasis. 皮肤利什曼病临床管理进展。
Skin therapy letter Pub Date : 2025-01-01
Zeyad Koussayer, Judy Koussayer, Stephen K Tyring
{"title":"An Update on the Clinical Management of Cutaneous Leishmaniasis.","authors":"Zeyad Koussayer, Judy Koussayer, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cutaneous leishmaniasis (CL) is an infection caused by the Leishmania protozoa, which are primarily transmitted through bites of infected female sandflies. This article provides a comprehensive overview of the clinical management of CL, including an in-depth analysis of its epidemiology, prevention and control measures, diagnostic modalities - particularly molecular and serological, differential diagnosis with other lesions, and treatment options. Also discussed are recent concerns regarding the endemicity of CL, with a focus on the significant rise in travel-related cases as well as locally acquired cases, providing insight into the changing epidemiological landscape.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 1","pages":"5-9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143011713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信